Biophytis S.A. (BPTSY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biophytis S.A. (BPTSY) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 45/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Biophytis S.A. (BPTSY) Gesundheitswesen & Pipeline-Uebersicht
Biophytis S.A. is a clinical-stage biotechnology company developing therapeutics for age-related diseases, including sarcopenia and macular degeneration. Their lead drug candidate, BIO101, addresses neuromuscular diseases and respiratory failure, positioning them in the regenerative medicine market with a focus on resilience pathways.
Investmentthese
Biophytis S.A. presents a high-risk, high-reward investment opportunity in the biotechnology sector. The investment thesis hinges on the successful clinical development and regulatory approval of BIO101 and BIO201. Key value drivers include positive clinical trial results, strategic partnerships, and potential market exclusivity. The company's focus on age-related diseases aligns with growing demographic trends and unmet medical needs. However, the company's negative P/E ratio of -0.07 reflects its current pre-revenue status. Investors should closely monitor clinical trial outcomes and regulatory milestones as key indicators of future success. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may not fully capture the inherent risks of investing in a clinical-stage biotech company.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Biophytis S.A. is a clinical-stage biotechnology company focused on age-related diseases.
- Lead drug candidate BIO101 targets neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD).
- BIO201 is being developed for retinopathies, such as dry age-related macular degeneration and Stargardt disease.
- Collaboration agreement with AFM-Telethon supports the development of BIO101 for DMD.
- The company's P/E ratio is -0.07, reflecting its pre-revenue status.
Wettbewerber & Vergleichsunternehmen
Staerken
- Novel approach targeting resilience pathways.
- Lead drug candidate BIO101 in clinical development.
- Collaboration with AFM-Telethon.
- Experienced management team.
Schwaechen
- Clinical-stage company with no current revenue.
- High reliance on successful clinical trial outcomes.
- Limited financial resources.
- OTC market trading with limited liquidity.
Katalysatoren
- Upcoming: Clinical trial results for BIO101 in sarcopenia patients.
- Upcoming: Clinical trial results for BIO101 in Duchenne Muscular Dystrophy (DMD) patients.
- Upcoming: Regulatory submissions for BIO101 in various indications.
- Ongoing: Advancement of BIO201 into clinical trials for AMD.
- Ongoing: Potential strategic partnerships and licensing agreements.
Risiken
- Potential: Clinical trial failures for BIO101 and BIO201.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and need for additional funding.
- Ongoing: OTC market trading with limited liquidity and transparency.
Wachstumschancen
- BIO101 for Sarcopenia: The global sarcopenia market is projected to reach billions of dollars by 2028, driven by the aging population and increasing awareness of muscle loss. BIO101's potential to improve muscle function and reduce the risk of falls presents a significant growth opportunity. Clinical trials are ongoing, and positive results could lead to regulatory approval and commercialization within the next 3-5 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- BIO101 for Duchenne Muscular Dystrophy (DMD): DMD is a rare genetic disorder with limited treatment options. BIO101's collaboration with AFM-Telethon provides access to expertise and resources for developing a therapy for DMD. The DMD market is expected to grow as new therapies emerge. Regulatory approval could be expedited through orphan drug designation. The timeline for commercialization depends on the success of clinical trials and regulatory review, potentially within 5-7 years.
- BIO101 for COVID-19 Respiratory Failure: The COVID-19 pandemic has highlighted the need for effective treatments for respiratory failure. BIO101's potential to reduce inflammation and improve lung function could address this unmet need. The market size depends on the ongoing prevalence of COVID-19 and the emergence of new variants. Regulatory approval could be accelerated through emergency use authorization. The timeline for commercialization is uncertain but could be within the next 1-3 years.
- BIO201 for Age-Related Macular Degeneration (AMD): AMD is a leading cause of vision loss in older adults. BIO201's potential to slow the progression of dry AMD represents a significant growth opportunity. The AMD market is expected to grow as the population ages. Clinical trials are planned, and positive results could lead to regulatory approval and commercialization within the next 5-7 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- Strategic Partnerships and Licensing Agreements: Biophytis can expand its pipeline and market reach through strategic partnerships and licensing agreements. Collaborating with larger pharmaceutical companies or other biotech firms can provide access to funding, expertise, and distribution networks. Licensing out certain assets can generate revenue and reduce financial risk. The timeline for these opportunities is variable but could occur within the next 1-3 years.
Chancen
- Growing market for age-related disease therapies.
- Potential for orphan drug designation for DMD.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
Risiken
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Economic downturn and reduced healthcare spending.
Wettbewerbsvorteile
- Proprietary drug candidates with patent protection.
- Focus on resilience pathways, a novel approach to treating age-related diseases.
- Collaboration with AFM-Telethon for DMD research.
- Expertise in developing orally administered small molecule drugs.
Ueber BPTSY
Biophytis S.A., founded in 2006 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to developing therapeutics that slow degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company's core strategy revolves around targeting and activating key biological resilience pathways, which protect against and counteract the effects of various biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that contribute to age-related diseases. Their lead drug candidate, BIO101, is an orally administered small molecule currently in development for treating neuromuscular diseases such as sarcopenia, Duchenne muscular dystrophy (DMD), and obesity. BIO101 is also being explored as a treatment for severe respiratory failure in patients suffering from COVID-19. In addition to BIO101, Biophytis is developing BIO201, another orally administered small molecule, aimed at treating retinopathies, including dry age-related macular degeneration and Stargardt disease. Biophytis has a collaboration agreement with AFM-Telethon for the development of BIO101 for DMD, highlighting strategic partnerships to advance their pipeline. The company employs 22 individuals.
Was das Unternehmen tut
- Develop therapeutics for age-related diseases.
- Target and activate key biological resilience pathways.
- Develop orally administered small molecule drugs.
- Focus on neuromuscular diseases like sarcopenia and DMD.
- Develop treatments for retinopathies like AMD.
- Collaborate with organizations like AFM-Telethon.
Geschaeftsmodell
- Develop and commercialize proprietary drug candidates.
- Out-license drug candidates to larger pharmaceutical companies.
- Generate revenue through strategic partnerships and collaborations.
- Secure funding through venture capital and public offerings.
Branchenkontext
Biophytis operates within the biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant market potential for successful therapies. The aging global population is driving increased demand for treatments targeting age-related diseases, creating a favorable market environment for companies like Biophytis. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Key trends include personalized medicine, gene therapy, and the use of artificial intelligence in drug discovery. Competitors include BITRF (BioTime Inc), BNGI (Bionomics Ltd), IPIX (Ipix Pharmaceuticals Inc), MCET (MGC Pharmaceuticals Ltd), and PFND (Profound Medical Corp).
Wichtige Kunden
- Patients suffering from age-related diseases.
- Healthcare providers who prescribe Biophytis's therapies.
- Pharmaceutical companies that may license or acquire Biophytis's drug candidates.
- Research institutions and organizations interested in collaborating with Biophytis.
Finanzdaten
Chart & Info
Biophytis S.A. (BPTSY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer BPTSY verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BPTSY.
Kursziele
Wall-Street-Kurszielanalyse fuer BPTSY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von BPTSY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Stanislas Veillet
CEO
Stanislas Veillet serves as the CEO of Biophytis S.A., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes roles in venture capital and business development, with a focus on identifying and developing innovative therapies. He has a strong understanding of the regulatory landscape and the challenges of bringing new drugs to market. His leadership is focused on advancing Biophytis's pipeline and securing strategic partnerships.
Erfolgsbilanz: Under Stanislas Veillet's leadership, Biophytis has advanced its lead drug candidate, BIO101, into clinical trials for multiple indications, including sarcopenia and DMD. He has also secured a collaboration agreement with AFM-Telethon, a significant milestone for the company. His strategic decisions have focused on targeting unmet medical needs in age-related diseases and building a strong intellectual property portfolio.
Biophytis S.A. ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. BPTSY is a Level 1 ADR, meaning it trades over-the-counter (OTC) and has less stringent reporting requirements than listed companies. It allows US investors to invest in Biophytis S.A. without directly dealing with foreign exchanges.
- Heimatmarkt-Ticker: Euronext Growth Paris, France
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: BPTS
BPTSY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biophytis S.A. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered more speculative and carries higher risks than exchange-listed stocks.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited liquidity and trading volume.
- Lack of financial transparency and disclosure.
- Higher potential for price manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight.
- Review the company's filings on the OTC Markets website.
- Assess the company's financial health and operational performance.
- Research the management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Consult with a financial advisor.
- Consider the risks associated with investing in OTC stocks.
- Established business operations in France.
- Lead drug candidate in clinical development.
- Collaboration agreement with AFM-Telethon.
- Experienced management team.
- Focus on addressing unmet medical needs.
BPTSY Healthcare Aktien-FAQ
What are the key factors to evaluate for BPTSY?
Biophytis S.A. (BPTSY) currently holds an AI score of 45/100, indicating low score. Key strength: Novel approach targeting resilience pathways.. Primary risk to monitor: Potential: Clinical trial failures for BIO101 and BIO201.. This is not financial advice.
How frequently does BPTSY data refresh on this page?
BPTSY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BPTSY's recent stock price performance?
Recent price movement in Biophytis S.A. (BPTSY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel approach targeting resilience pathways.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BPTSY overvalued or undervalued right now?
Determining whether Biophytis S.A. (BPTSY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BPTSY?
Before investing in Biophytis S.A. (BPTSY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BPTSY to a portfolio?
Potential reasons to consider Biophytis S.A. (BPTSY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Novel approach targeting resilience pathways.. Additionally: Lead drug candidate BIO101 in clinical development.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of BPTSY?
Yes, most major brokerages offer fractional shares of Biophytis S.A. (BPTSY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BPTSY's earnings and financial reports?
Biophytis S.A. (BPTSY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BPTSY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.